Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 31

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 31
---
120,469)TOTAL OPERATING EXPENSES  (80,855)  (415,629)  (149,422)  (645,906)                 (LOSS)/PROFIT FROM OPERATIONS  (41,248)  111,642   (149,422)  (79,028)                 FINANCE COSTS  (1,950)  (2,687)  (24)  (4,661)                 (LOSS)/PROFIT BEFORE TAX  (43,198)  108,955   (149,446)  (83,689)                 Tax expense  -   (20,068)  -   (20,068)                 NET (LOSS)/PROFIT ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(43,198) $88,887  $(149,446) $(103,757)

 25Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   As of March 31, 2025              Segment assets  $2,557,978  $6,108,859  $813,102  $9,479,939                  Included in the measure of segment assets are:                                 Addition to non-current assets other than financial instruments and deferred tax assets  -   9,052   -   9,052     As of December 31, 2024              Segment assets  $2,652,754  $6,788,302  $992,792  $10,433,848                  Included in the measure of segment assets are:                                 Addition to non-current assets other than financial instruments and deferred tax assets  150,881   221,844   -   372,725 

The Company had no inter-se